| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Kiely John is a Director at AMRX. Recent filings cover 1 purchase and 4 sales. Those positions are worth an estimated $3.7M at current prices.
Our model assigns Kiely John a below-average insider score of 22/100, based on 3 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -54.1%.
Kiely John's largest disclosed position is in AMRX as Director, worth about $3.7M. The recent filings there lean toward selling, a net 139,058 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Director | Sell | 50,000 | $17.64 | $882,000.00 | -19.2% | - | - | |
| Aug 27, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Director | Sell | 32,000 | $9.23 | $295,360.00 | -12.4% | +32.9% | +92.4% | |
| May 12, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Director | Sell | 50,000 | $7.59 | $379,500.00 | -16.3% | +16.3% | +65.8% | |
| Nov 22, 2024 | AMRX Amneal Pharmaceuticals, Inc. | Director | Sale+OE | 17,058 | $8.38 | $142,946.04 | -6.0% | -6.2% | +42.4% | |
| May 19, 2020 | AMRX Amneal Pharmaceuticals, Inc. | Director | Buy | 10,000 | $4.40 | $44,000.00 | New | - | - |